← All trials
NCT05695781
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2023
- Primary completion
- Dec 30, 2023
- Completion date
- Mar 30, 2024
- First posted
- Jan 25, 2023
- Last posted
- Sep 18, 2023
- Enrollment
- 732
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BRIM Biotechnology Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.